Dabigatran: Are There Any Concerns? - Neal Kleiman, MD, FSCAI

↳ This is a section part of Moment: CRT 2016 Coronary - The Oral Factor Xa Inhibitor Controversy

Add this Moment to your Passport

Learn from this moment and keep it forever.
add to passport
$12.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Dabigatran: Are There Any Concerns? presented by Neal Kleiman, MD, FSCAI at CRT 2016

Add this Moment to your Passport

Learn from this moment and keep it forever.
add to passport
$12.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

  • Interventional Cardiologists
  • Interventional Fellows

Session Name: The Oral Factor Xa Inhibitor Controversy

Track: Coronary

Learning Objectives

  • Update in advances in ACS & AMI Management

Other Components in this Moment

Overview
Oral Anticoagulants for Atrial Fibrillation: Is There a Winner? - C. Michael Gibson, MD
Dabigatran: Are There Any Concerns? - Neal Kleiman, MD, FSCAI
Should We Combine Antiplatelet Therapy with Oral Factor Xa Inhibitors? - Dominick Angiolillo, MD, PhD, FSCAI
Rivaroxaban in Patients with ACS: Do the Data Provide Support? - C. Michael Gibson, MD
What Did We Learn from the WOEST Studies and Protocols? Are We Ready to Drop Aspirin From Triple Therapy? - Sunil Rao, MD, FSCAI
Is RNA Aptamer Technology Dead? - A. Michael Lincoff, MD
Loading Simple Education